This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2006 Feb 1;24(4):533-6.

doi: 10.1200/JCO.2005.03.8299. Epub 2006 Jan 3.

Cytotoxic anticancer agents and renal impairment study: the challenge remains

Atiqur Rahman, Robert M White

PMID: 16391294
DOI: 10.1200/JCO.2005.03.8299

Review

Cytotoxic anticancer agents and renal impairment study: the challenge remains

Atiqur Rahman et al. J Clin Oncol. 2006.

. 2006 Feb 1;24(4):533-6.

doi: 10.1200/JCO.2005.03.8299. Epub 2006 Jan 3.

Authors

Atiqur Rahman, Robert M White

PMID: 16391294
DOI: 10.1200/JCO.2005.03.8299

No abstract available

PubMed Disclaimer

Comment in

Design, conduct, and interpretation of organ impairment studies in oncology patients.
Takimoto CH, Mita AC. Takimoto CH, et al. J Clin Oncol. 2006 Jul 20;24(21):3509-10; author reply 3510-1. doi: 10.1200/JCO.2006.06.6795. J Clin Oncol. 2006. PMID: 16849773 No abstract available.

Comment on

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Mita AC, et al. J Clin Oncol. 2006 Feb 1;24(4):552-62. doi: 10.1200/JCO.2004.00.9720. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391300 Clinical Trial.

Similar articles

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Mita AC, et al. J Clin Oncol. 2006 Feb 1;24(4):552-62. doi: 10.1200/JCO.2004.00.9720. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391300 Clinical Trial.
Design, conduct, and interpretation of organ impairment studies in oncology patients.
Takimoto CH, Mita AC. Takimoto CH, et al. J Clin Oncol. 2006 Jul 20;24(21):3509-10; author reply 3510-1. doi: 10.1200/JCO.2006.06.6795. J Clin Oncol. 2006. PMID: 16849773 No abstract available.
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. Latz JE, et al. Cancer Chemother Pharmacol. 2006 Apr;57(4):412-26. doi: 10.1007/s00280-005-0077-5. Epub 2005 Dec 2. Cancer Chemother Pharmacol. 2006. PMID: 16322990
Pemetrexed safety and dosing strategy.
Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA Jr. Niyikiza C, et al. Semin Oncol. 2002 Dec;29(6 Suppl 18):24-9. doi: 10.1053/sonc.2002.37465. Semin Oncol. 2002. PMID: 12571807 Review.
The potential role of pemetrexed in gastrointestinal cancer.
Meriggi F, Di Biasi B, Caliolo C, Zaniboni A. Meriggi F, et al. Chemotherapy. 2008;54(1):1-8. doi: 10.1159/000112311. Epub 2007 Dec 7. Chemotherapy. 2008. PMID: 18063861 Review.

See all similar articles

Cited by

Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application.
Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Hendrayana T, et al. Sci Pharm. 2017 Feb 27;85(1):8. doi: 10.3390/scipharm85010008. Sci Pharm. 2017. PMID: 28264440 Free PMC article.
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A, Martin P, Smith R, Oliver S, Langmuir P, Read J, Molz KH. Weil A, et al. Clin Pharmacokinet. 2010 Sep;49(9):607-18. doi: 10.2165/11534330-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20690783
Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error.
van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. van Hasselt JG, et al. Invest New Drugs. 2014 Oct;32(5):913-27. doi: 10.1007/s10637-014-0103-8. Epub 2014 May 2. Invest New Drugs. 2014. PMID: 24788562

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information